AMPLIFY - D6571C00001 Duaklir USA Phase III Study

NCT ID: NCT02796677

Last Updated: 2018-11-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 1595 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-07-05
• Study Completion Date: 2017-06-08

Brief Summary

This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared to individual components and TIO (Tiotropium) 18 μg when administered to patients with stable chronic obstructive pulmonary disease (COPD).

Detailed Description

This study was conducted to assess the bronchodilator efficacy and safety as well as effect on health related quality of life of AB/FF 400/12 μg compared to the individual components (AB 400 μg and FF 12 μg) in COPD patients. The trial duration of 24 weeks allows the assessment of the effect on symptoms improvement of the combined treatments versus individual components as well as the long term bronchodilation comparison between AB 400 μg and TIO 18 μg in minimizing the risk of COPD exacerbations in current or former smokers, aged ≥40 in symptomatic COPD patients.

Conditions

Chronic Obstructive Pulmonary Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

AB/FF 400/12 μg BID

Participants were administered AB/FF 400/12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.

Group Type: EXPERIMENTAL

Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)

Intervention Type: DRUG

Inhalation powder

Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg

Intervention Type: OTHER

Inhalation powder

AB 400 μg BID

Participants were administered AB 400 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.

Group Type: EXPERIMENTAL

Aclidinium bromide 400 μg (AB 400 μg)

Intervention Type: DRUG

Inhalation powder

Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg

Intervention Type: OTHER

Inhalation powder

FF 12 μg BID

Participants were administered FF 12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.

Group Type: EXPERIMENTAL

Formoterol fumarate 12 μg (FF 12 μg)

Intervention Type: DRUG

Inhalation powder

Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg

Intervention Type: OTHER

Inhalation powder

TIO 18 μg QD

Participants were administered TIO 18 μg via Handihaler® inhale once daily for 24 weeks of treatment.

Group Type: EXPERIMENTAL

Tiotropium 18 μg (TIO 18 μg)

Intervention Type: DRUG

Powder in capsules for oral inhalation

Placebo to TIO 18 μg

Intervention Type: OTHER

Powder in capsules for oral inhalation

Interventions

Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)

Inhalation powder

Intervention Type: DRUG

Aclidinium bromide 400 μg (AB 400 μg)

Inhalation powder

Intervention Type: DRUG

Formoterol fumarate 12 μg (FF 12 μg)

Inhalation powder

Intervention Type: DRUG

Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg

Inhalation powder

Intervention Type: OTHER

Tiotropium 18 μg (TIO 18 μg)

Powder in capsules for oral inhalation

Intervention Type: DRUG

Placebo to TIO 18 μg

Powder in capsules for oral inhalation

Intervention Type: OTHER

Other Intervention Names

Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler); Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler); Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler); Oral Inhalation (by Pressair®/Genuair® Dry Powder Inhaler); Oral Inhalation (by Handihaler® Dry Powder Inhaler, DPI); Oral Inhalation (by Handihaler® Dry Powder Inhaler, DPI)

Eligibility Criteria

Inclusion Criteria

• Adult male or non-pregnant, non-lactating female patients aged ≥40.
• Patients with diagnosis of moderate to very severe stable COPD: post-bronchodilator FEV1 < 80% of the predicted normal and post-bronchodilator FEV1/FVC < 70% at Screening Visit.
• Symptomatic patients with a CAT score ≥10 at Screening and Randomization visit (Visits 1 and 2).
• Current or former-smokers, with a smoking history of ≥ 10 pack-years.
• Patients able to perform acceptable and repeatable pulmonary function testing for FEV1 according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) 2005 criteria at Visit 1.
• Patients eligible and able to participate in the study and who had signed an Informed Consent Form prior to initiation of any study-related procedures.

Exclusion Criteria

• Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff and/or site staff), or patients employed by or relatives of the employees of the site or sponsor.
• Previous randomization in the present study D6571C00001.
• Patients with predominant asthma.
• Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation (including the mild COPD exacerbation) within 6 weeks prior to screening or during the run-in period.
• Patients hospitalized for a COPD exacerbation (an emergency room visit for longer than 24 hours is considered a hospitalization) within 3 months prior to Screening Visit.
• Clinically significant respiratory conditions other than COPD.
• Patients who in the Investigator's opinion may need to start a pulmonary rehabilitation program during the study and/or patients who started/finished it within 3 months prior to Screening.
• Use of long-term oxygen therapy (≥ 15 hours/day).
• Patients who do not maintain regular day/night, waking/sleeping cycles including night shift workers.
• Clinically significant cardiovascular conditions.
• Patients with uncontrolled Type I or Type II diabetes, uncontrolled hypo-or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled hypertension.
• Patients with history of long QT syndrome or whose QTc (calculated according to Fridericia's Formula QTc=QT/RR1/3) > 470 ms as indicated in the centralised reading report assessed at Screening.
• Patients with clinically significant abnormalities in the laboratory tests, ECG parameters (other than QTc) or in the physical examination at Screening Visit that might comprise patient safety.
• Patient with known non-controlled history of infection with human immunodeficiency virus and/or active hepatitis.
• Patient with a history of hypersensitivity reaction to inhaled medication or any component thereof, including paradoxical bronchospasm.
• Patients with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention or symptomatic non-stable prostate hypertrophy.
• History of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer.
• Patients with any other serious or uncontrolled physical or mental dysfunction.
• Patients with a history (within 2 years prior to screening) of drug and/or alcohol abuse that may prevent study compliance based on the Investigator judgment.
• Patients unlikely to be cooperative or that cannot comply with the study procedures.
• Patients treated with any investigational drug within 30 days (or 6 half-lives, whichever is longer) prior to Screening.
• Patients who intended to use any concomitant medication not permitted by this protocol or who had not undergone the required washout period for a particular prohibited medication.
• Patients unable to give consent, or patients of consenting age but under guardianship, or vulnerable patients. Patients who demonstrate < 80% compliance with the electronic diary during the run-in period.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 130 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sanjay Sethi

Role: PRINCIPAL_INVESTIGATOR

3495 Bailey Ave , Buffalo NY14215, USA

Locations

Research Site

Gulf Shores, Alabama, United States

Research Site

Phoenix, Arizona, United States

Research Site

Tucson, Arizona, United States

Research Site

Corona, California, United States

Research Site

Fresno, California, United States

Research Site

Fullerton, California, United States

Research Site

Lincoln, California, United States

Research Site

San Diego, California, United States

Research Site

Waterbury, Connecticut, United States

Research Site

Clearwater, Florida, United States

Research Site

Edgewater, Florida, United States

Research Site

Hollywood, Florida, United States

Research Site

Homestead, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Miami Lakes, Florida, United States

Research Site

Ormond Beach, Florida, United States

Research Site

Port Orange, Florida, United States

Research Site

Sarasota, Florida, United States

Research Site

St. Petersburg, Florida, United States

Research Site

St. Petersburg, Florida, United States

Research Site

Tampa, Florida, United States

Research Site

Winter Park, Florida, United States

Research Site

Blue Ridge, Georgia, United States

Research Site

Woodstock, Georgia, United States

Research Site

Chicago, Illinois, United States

Research Site

Portage, Indiana, United States

Research Site

Lafayette, Louisiana, United States

Research Site

Fall River, Massachusetts, United States

Research Site

Chelsea, Michigan, United States

Research Site

Farmington Hills, Michigan, United States

Research Site

Troy, Michigan, United States

Research Site

Edina, Minnesota, United States

Research Site

Fridley, Minnesota, United States

Research Site

Minneapolis, Minnesota, United States

Research Site

Woodbury, Minnesota, United States

Research Site

Saint Charles, Missouri, United States

Research Site

St Louis, Missouri, United States

Research Site

St Louis, Missouri, United States

Research Site

Fremont, Nebraska, United States

Research Site

Omaha, Nebraska, United States

Research Site

Omaha, Nebraska, United States

Research Site

Las Vegas, Nevada, United States

Research Site

Brooklyn, New York, United States

Research Site

Buffalo, New York, United States

Research Site

New York, New York, United States

Research Site

Rochester, New York, United States

Research Site

The Bronx, New York, United States

Research Site

Charlotte, North Carolina, United States

Research Site

Charlotte, North Carolina, United States

Research Site

Gastonia, North Carolina, United States

Research Site

Wilmington, North Carolina, United States

Research Site

Canton, Ohio, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Columbus, Ohio, United States

Research Site

Columbus, Ohio, United States

Research Site

Dublin, Ohio, United States

Research Site

Grove City, Ohio, United States

Research Site

Edmond, Oklahoma, United States

Research Site

Midwest City, Oklahoma, United States

Research Site

Oklahoma City, Oklahoma, United States

Research Site

Medford, Oregon, United States

Research Site

Altoona, Pennsylvania, United States

Research Site

Pittsburgh, Pennsylvania, United States

Research Site

Wyomissing, Pennsylvania, United States

Research Site

East Providence, Rhode Island, United States

Research Site

Columbia, South Carolina, United States

Research Site

Gaffney, South Carolina, United States

Research Site

Mt. Pleasant, South Carolina, United States

Research Site

Spartanburg, South Carolina, United States

Research Site

Union, South Carolina, United States

Research Site

Arlington, Texas, United States

Research Site

Baytown, Texas, United States

Research Site

Boerne, Texas, United States

Research Site

Dallas, Texas, United States

Research Site

Fort Worth, Texas, United States

Research Site

Houston, Texas, United States

Research Site

Lewisville, Texas, United States

Research Site

McKinney, Texas, United States

Research Site

Tomball, Texas, United States

Research Site

Midvale, Utah, United States

Research Site

Abingdon, Virginia, United States

Research Site

Newport News, Virginia, United States

Research Site

Dimitrovgrad, , Bulgaria

Research Site

Gabrovo, , Bulgaria

Research Site

Roman, , Bulgaria

Research Site

Rousse, , Bulgaria

Research Site

Sevlievo, , Bulgaria

Research Site

Sliven, , Bulgaria

Research Site

Sofia, , Bulgaria

Research Site

Sofia, , Bulgaria

Research Site

Stara Zagora, , Bulgaria

Research Site

Vidin, , Bulgaria

Research Site

Jaroměř, , Czechia

Research Site

Jindřichův Hradec, , Czechia

Research Site

Prague, , Czechia

Research Site

Rokycany, , Czechia

Research Site

Strakonice, , Czechia

Research Site

Berlin, , Germany

Research Site

Berlin, , Germany

Research Site

Berlin, , Germany

Research Site

Berlin, , Germany

Research Site

Berlin, , Germany

Research Site

Bochum, , Germany

Research Site

Dortmund, , Germany

Research Site

Dresden, , Germany

Research Site

Frankfurt, , Germany

Research Site

Großhansdorf, , Germany

Research Site

Hamburg, , Germany

Research Site

Hamburg, , Germany

Research Site

Hamburg, , Germany

Research Site

Hanover, , Germany

Research Site

Leipzig, , Germany

Research Site

Leipzig, , Germany

Research Site

Lübeck, , Germany

Research Site

Marburg, , Germany

Research Site

München, , Germany

Research Site

Schwerin, , Germany

Research Site

Balassagyarmat, , Hungary

Research Site

Budapest, , Hungary

Research Site

Debrecen, , Hungary

Research Site

Gödöllő, , Hungary

Research Site

Komló, , Hungary

Research Site

Nyíregyháza, , Hungary

Research Site

Pécs, , Hungary

Research Site

Szigetszentmiklós, , Hungary

Research Site

Szombathely, , Hungary

Research Site

Jerusalem, , Israel

Research Site

Petah Tikva, , Israel

Research Site

Rehovot, , Israel

Research Site

Bialystok, , Poland

Research Site

Częstochowa, , Poland

Research Site

Gdansk, , Poland

Research Site

Gdynia, , Poland

Research Site

Inowrocław, , Poland

Research Site

Katowice, , Poland

Research Site

Ostrowiec Świętokrzyski, , Poland

Research Site

Pabianice, , Poland

Research Site

Szczecin, , Poland

Research Site

Warsaw, , Poland

Research Site

Wroclaw, , Poland

Research Site

Zabrze, , Poland

Research Site

Alicante, , Spain

Research Site

Barcelona, , Spain

Research Site

Lleida, , Spain

Research Site

Ivano-Frankivsk, , Ukraine

Research Site

Kharkiv, , Ukraine

Research Site

Kharkiv, , Ukraine

Research Site

Odesa, , Ukraine

Research Site

Poltava, , Ukraine

Research Site

Sumy, , Ukraine

Research Site

Uzhhorod, , Ukraine

Research Site

Vinnytsia, , Ukraine

Research Site

Zhytomyr, , Ukraine

Research Site

Birmingham, , United Kingdom

Research Site

Cardiff, , United Kingdom

Research Site

Chorley, , United Kingdom

Research Site

Glasgow, , United Kingdom

Research Site

Hexham, , United Kingdom

Research Site

Liverpool, , United Kingdom

Research Site

Manchester, , United Kingdom

Countries

United States; Bulgaria; Czechia; Germany; Hungary; Israel; Poland; Spain; Ukraine; United Kingdom

References

Sethi S, Kerwin E, Watz H, Ferguson GT, Mroz RM, Segarra R, Molins E, Jarreta D, Garcia Gil E. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. Int J Chron Obstruct Pulmon Dis. 2019 Mar 22;14:667-682. doi: 10.2147/COPD.S189138. eCollection 2019.

Reference Type: DERIVED

PMID: 30962681 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4098&filename=D6571C00001-Protocol-Final-redacted-06Jun2018(PdfA).pdf

Protocol

http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4098&filename=D6571C00001-SAP-Amendment-1-Final-redacted-06Jun2018(PdfA).pdf

SAP

Other Identifiers

D6571C00001

Identifier Type: -

Identifier Source: org_study_id